Ultragenyx Pharmaceutical (RARE) Misses Q3 EPS by 4c

Ultragenyx Pharmaceutical (NASDAQ: RARE) reported Q3 EPS of ($0.50), $0.04 worse than the analyst estimate of ($0.46).

For earnings history and earnings-related data on Ultragenyx Pharmaceutical (RARE) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Creatd files Form S-1 and reports Q1 2026 financial results
• Wealthfront launches custodial account with tax-gain harvesting